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Abstract	
	
In	vitro	protein	selection	has	had	major	impacts	in	the	field	of	protein	engineering.	Traditional	screens	assay	individual	proteins	for	specific	function.	Selection,	however,	analyzes	a	pool	of	mutants	and	yields	the	best	variants.	Phage	display,	a	successful	selection	technique,	also	provides	a	reliable	link	between	variant	phenotype	and	genotype.	It	can	also	be	coupled	with	high	throughput	sequencing	to	map	protein	mutations;	potentially	highlighting	vital	mutations	in	variants.	We	propose	to	apply	this	technique	to	cancer	therapy.	RAF,	a	serine/threonine	kinase,	is	critical	for	cell	regulation	in	mammals.	RAF	can	be	activated	by	oncogenic	RAS,	found	in	over	30%	of	cancers,	to	drive	cancer	proliferation.	Rigosertib,	a	benzyl	styryl	sulfone	in	phase	III	clinical	trials	for	myelodysplastic	syndrome	(MDS),	is	an	inhibitor	of	the	RAS	binding	domain	(RBD)	in	RAF.	Phage	display	can	be	used	to	select	RAF	mutants	for	RAS	binding	affinity,	in	the	presence	of	Rigosertib.	High-throughput	sequencing	of	these	variants	can	provide	a	means	of	anticipating,	and	mapping	resistance	to	this	anti-cancer	drug.	
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Summary	
In	vitro	protein	selection	has	had	major	impacts	in	the	field	of	protein	engineering	and	analysis.	While	traditional	screens	assay	individual	mutants	or	proteins	of	interest	for	specific	function,	selection	analyzes	a	pool	of	mutants	by	subjecting	them	to	a	set	of	conditions	that	are	designed	to	yield	the	best	variants.	Selection,	however,	is	plagued	by	the	difficulty	of	accurately	identifying	the	genotypes	of	selected	variants.	Phage	display	is	a	successful	selection	technique	that	provides	a	reliable	link	between	protein	and	genotype.	Ff	bacteriophage	can	display	non-native	proteins	alongside	its	coat	proteins.	This	is	accomplished	by	cloning	a	protein	of	interest	into	the	genome	of	Ff	bacteriophage,	which	results	in	the	display	of	that	protein	on	the	phage	coat.	Thus,	a	single	phage	links	the	genotype	and	phenotype	of	the	protein	that	its	genome	includes.	Furthermore,	once	cloned	into	a	phage	genome,	a	protein	can	be	diversified	to	create	a	mutant	library.	This	library	of	phage	can	be	selected	for	specific	function	effectively	and	efficiently.	Selected	phage	can	then	be	characterized	via	high	throughput	sequencing	to	map	vital	protein	mutations;	highlighting	mutations	conserved	across	multiple	variants	that	may	be	involved	with	the	function	of	interest.		The	coupling	of	selection	and	high	throughput	sequencing	can	have	major	implications	for	cancer	therapy.	RAS	is	a	small-GTPase	membrane	bound	protein,	primarily	involved	with	signal	transmission	in	cells.	Oncogenic	mutations	in	RAS	have	found	in	over	30%	of	cancers.	RAS	oncogenes	are	involved	in	signal	transduction	pathways	that	affect	cell	apoptosis,	proliferation,	and	division,	and	can	initiate	or	perpetuate	human	carcinomas.	RAF	is	a	serine/threonine	kinase	directly	downstream	of	RAS.	RAF	is	critical	for	cell	growth	and	regulation	in	mammals	via	its	role	in	the	cytoplasmic	kinase	cascade	signaling	pathway.	Oncogenic	RAS	has	been	found	to	impact	tumor	growth	through	the	RAF-mediated	pathway.	Because	RAS	is	involved	in	a	number	of	cellular	pathways,	drugs	that	specifically	inhibit	binding	between	RAS	and	RAF	can	affect	the	mutagenic	effects	of	oncogenic	RAS	without	adversely	impacting	other	vital	RAS	function	in	the	cell.	Rigosertib,	a	benzyl	styryl	sulfone	in	phase	III	clinical	trials	for	myelodysplastic	syndrome	(MDS),	is	a	small	molecule	inhibitor	of	the	RAS	binding	domain	of	RAF	(RBD).	It	is	possible	that	RAF	may	develop	a	functional	resistance	mutation	that	reduces	Rigosertib	binding	affinity,	while	retaining	RAS	binding	affinity.	By	combining	phage	display	selection	of	RAF	variants,	with	high-throughput	sequencing	we	can	understand	and	map	RAF	resistance	to	Rigosertib.	This	information	can	be	used	to	enhance	current	and	future	cancer	therapeutics.	A	library	of	RAF	mutants	will	be	successfully	displayed	on	Ff	bacteriophage.	This	library	will	then	undergo	a	selection	strategy	that	will	procure	variants	with	high	binding	affinity	to	RAS	in	the	presence	of	Rigosertib.	We	can	infer	that	these	variants	have	developed	resistance	to	the	anti-cancer	drug.	Following	selection,	these	variants	will	be	characterized	by	high-throughput	sequencing,	and	functional	resistance	mutations	will	be	identified.	Lastly,	selected	variants	will	be	tested	for	functionality	in	
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downstream	signaling	interactions;	the	development	of	resistance	is	not	entirely	effective	if	downstream	function	is	impaired,	and	signal	transduction	cannot	occur.	
Experimental	Aim	1:	Create	library	of	RAF	mutants	and	confirm	phage	display	by	selecting	
for	mutant	binding	affinity	to	RAS	
Experimental	Aim	2:	Use	phage	display	to	identify	RAF	mutants	that	exhibit	resistance	to	
Rigosertib,	while	simultaneously	retaining	binding	affinity	to	RAS	
Experimental	Aim	3:	Test	selected	mutants	for	functionality	within	the	RAF-MEK-ERK	
pathway	
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A. Phage	Display	
In	vitro	protein	selection	has	gained	ground	in	the	field	of	protein	engineering	and	analysis.1	Selection	techniques	are	a	better	tool	than	screens	for	analyzing	and	specifying	molecular	function	and	efficiency.	Screens	assay	individual	mutants	or	proteins	of	interest	for	specific	function,	resulting	in	the	identification	of	the	best	protein	within	the	batch.	The	method	of	selection,	on	the	other	hand,	is	the	analysis	of	a	pool	of	variants,	or	mutants,	under	a	set	of	selection	conditions	that	yield	the	most	efficient	or	functional	variants.1	In	the	past,	the	difficulty	associated	with	selection	methods	was	grounded	in	identifying	a	realistic	and	efficient	method	with	which	to	link	genotype	with	the	yielded	proteins.1	Phage	display	has	provided	a	method	with	which	to	select	for	specific	function	and	efficiency,	while	simultaneously	providing	a	reliable	link	between	protein	and	genotype.	Filamentous	phage	is	used	as	a	base	for	the	display	of	peptides	and	proteins,	while	containing	the	desired deoxyribonucleic	acid	(DNA)	sequence	within	its	genome.2	The	method	was	initially	described	by	Smith	in	1985,3	and	has	since	been	utilized	to	alter	the	function	of	polypeptides,	and	discover	novel	properties.	It	can	even	be	used	in	conjunction	with	high	throughput	sequencing	to	map	protein	mutations,	and	identify	amino	acid	mutations	that	are	integral	to	novel	protein	function	or	increased	efficiency.4	Phage	display	follows	a	simple	scheme,	as	described	in	Figure	1.	A	protein	of	interest	and	a	substrate	are	identified.5	The	protein	and	substrate	can	represent	protein-protein,	protein-peptide,	or	protein-DNA	interactions,	among	others.2,6	The	gene	encoding	the	protein	of	interest	is	then	inserted	into	the	bacteriophage	genome,	and	expressed	on	the	phage’s	coat	proteins.2	Selection	(for	
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binding,	affinity,	catalysis,	etc.)	is	completed	via	washing	and	elution	of	phages	under	various	selection	parameters.	
	
Figure 1. Schematic displaying a general 
phage display experiment. 		
A.1. Phage	Biology	
	 Ff	filamentous	Escherichia	coli	bacteriophage	are	most	commonly	used	in	phage	display.7	These	bacteriophages	have	proven	ideal	for	phage	display	for	a	number	of	reasons.	They	are	stable	in	a	range	of	selection	parameters.	The	filamentous	phage	genome	is	relatively	small,	about	6400	nucleotides,	and	tolerates	insertions	in	a	number	of	non-essential/non-coding	regions.2,7	The	phage	does	not	kill	the	host	cell,	and	thus	
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can	replicate	in	high	volumes.2,6	Lastly,	the	bacteriophage	coat	can	be	mutated	or	alerted	while	retaining	the	phage’s	infectivity.2	
A.1.1. Structure	The	structure	and	function	of	Filamentous	bacteriophages	has	been	widely	studied.	The	Ff	class	of	filamentous	phage	is	made	up	of	f1,	fd,	and	M13,	which	are	all	f-pilus	dependent	viruses;	they	use	the	F	conjugative	pilus	as	a	receptor.2,6	These	bacteriophages	encase	a	circular,	single-stranded,	DNA	genome	in	a	long	protein	capsid	cylinder.2,6,7	The	phage	genome	encodes	for	11	proteins	in	total	(Figure	2).	Two	proteins	are	involved	with	phage	export,	the	entire	capsid	is	made	up	of	five	coat	proteins,	and	the	other	four	proteins	are	minor	coat	proteins	and	are	used	for	cell	infection,	and	phage	replication.2	
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Figure 2. Ff bacteriophage proteins and functions. 
 The	gene	VIII	protein	(pVIII),	the	major	coat	protein,	is	comprised	of	50	amino	acids	and	composes	the	protein	cylinder	that	encapsulates	the	phages	single-stranded	DNA	(ssDNA).6	pVIII	molecules	pack	tightly,	overlapping	like	fishscales,2	to	form	a	right-handed	helix.	Phage	particles	have	a	fixed	diameter	of	6.5	nm,	and	their	length	is	determined	by	their	genome	size.2	For	example,	the	length	of	the	6400	nucleotide	ssDNA	Ff	phage	particle	is	930	nm,6	while	the	length	of	a	smaller	variant	of	with	221	nucleotides	is	50	nm.8	Thus,	genome	insertions	result	in	longer	phages.	In	order	to	contain	these	insertions,	the	phage	elongates	by	producing	more	pVIII	proteins.7	The	
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length	of	an	insertion	must,	however,	be	considered	since	longer	phages	can	be	prone	to	instability	and	breakage	(Figure	3).2	
	
Figure 3. Gene insertions into the phage genome elongate the 
phage particle. The phage accomplishes this by producing and 
incorporating more pVIII capsid proteins in the major coat. 
 One	end	of	the	phage	contains	about	5	copies	of	both	the	gene	VII	and	gene	IX	proteins	(pVII	and	pIX).6	pVII,	33	residues,	and	pIX,	32	residues,	are	located	at	the	end	of	the	phage	where	the	genome’s	packaging	signal	is	located.6	Phage	assembly	begins	at	this	end	of	the	phage,	and	both	proteins	are	vital	for	phage	formation.2	The	other	end	of	the	phage	house	5	copies	of	both	the	gene	III	and	gene	VI	proteins	(pIII	and	pVI).6	pIII,	406	residues,	is	composed	of	three	glycine-rich	regions	(Figure	4).6	Two	of	the	regions	are	required	for	cell	infection;	one	is	required	for	binding	to	the	cell	membrane,	and	the	other	is	necessary	for	the	transportation	of	phage	genome	into	the	cytoplasm	and	insertion	of	phage	proteins	into	the	cell	membrane.6	The	third	glycine-rich	region	is	necessary	for	the	formation	of	stable	phage	particles.6,9,10	This	third	pIII	region,	along	with	pVI,	112	residues,	interacts	with	pVIII	to	form	the	second	end	of	the	phage	particle.11	Both	of	these	proteins	are	involved	in	the	detachment	of	newly	formed	phage	from	host	cell	membranes.2	Not	much	else	is	known	
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about	the	function	of	pVI,	except	that	it	seems	to	form	a	complex	with	pIII,12,13	and	that	it	degrades	in	the	absence	of	pIII.11	
	
Figure 4. Structure of pIII and 
fusion points for display on phage. 
The CT domain (residues 257-
406) is embedded in the phage 
particle, while the N domains (N1; 
residues 1-68, and N2; residues 
87-217) are exposed. Glycine-rich 
linker regions connect the three 
domains (Gly1 and Gly2). 
Positions 198 and 249 are typical 
positions for protein of interest 
gene fusion. Image adapted from 
Ref. 2. 
 
A.1.2. Cell	Infection	The	f-pilus	dependency	of	Ff	bacteriophages,	indicates	that	these	phages	typically	infect	bacteria	cells	that	express	and	display	F	pili	on	their	cell	membranes.2,6	These	pili	exhibit	normal	assembly-retraction	cycles,6	in	which	they	continuously	extend	upon	assembly	and	retract	upon	disassembly.2	Binding	of	the	phage	pIII	to	an	F	pilus	retracts	the	pilus	and	brings	the	phage	into	close	proximity	of	the	cell	surface.6	
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Once	the	phage	is	close	to	the	cell	membrane,	another	domain	within	pIII	binds	to	a	co-receptor	Tol	protein	(the	F	pilus	is	the	receptor).2	Interaction	of	the	pIII	end	of	the	phage	with	the	host	cell’s	Tol	proteins	is	vital	for	phage	infection.14,15	Upon	infection,	the	phage’s	single	stranded	DNA	genome	is	translocated	into	the	cell’s	cytoplasm,	while	the	phage	coat	proteins	are	embedded	within	the	cell	membrane,	where	they	await	phage	replication.2,6	
A.1.3. Phage	Replication	Phage	replication	can	be	separated	into	three	distinct	stages.		First,	the	phage’s	single-stranded	DNA	is	converted	into	a	double-stranded	molecule	called	replicative	form	(RF)	via	the	host	cells	RNA	and	DNA	polymerases	and	topoisomerase.2	The	bacteria’s	replicative	enzymes	and	molecules	replicate	the	original	viral	single-stranded	DNA,	+	strand,	to	form	a	complimentary	–	strand,	producing	the	RF.	The	RF	is	then	transcribed	into	mRNA.	Lastly,	the	cellular	ribosomes	then	translate	the	mRNA	into	proteins.	These	proteins	are	transported	to	the	cell	membrane,	where	they	are	embedded	for	phage	release.	The	second	stage	of	the	replication	process	is	initiated	by	the	gene	II	protein	(pII).2	The	+	strand	of	the	RF	is	nicked	by	pII,	producing	a	free	3’	end	in	the	DNA	strand.	DNA	polymerase	then	elongates	the	+	strand	DNA,	beginning	at	the	3’	end	and	using	the	–	strand	as	template.	DNA	polymerase	is	further	assisted	by	pII,	which	unwinds	the	+	strand	through	a	rolling	circle	mechanism,	thus,	allowing	DNA	polymerase	to	fully	replicate	the	DNA	strand.2	Lastly,	the	new	+	strand	is	recircularized	by	pII,	and	converted	into	another	RF	molecule.	
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	 The	third	stage	of	replication	is	initiated	by	the	gene	V	protein	(pV).	In	the	early	stages	of	infection/replication	the	concentration	of	pV	is	low,	and	single-stranded	DNA	particles	are	converted	into	RF	with	little	inhibition.2	As	more	RF	is	accumulated,	and	the	concentration	of	expressed	phage	proteins	increases,	the	presence	of	pV	affects	the	replication	cycle.	pV	is	a	binding	protein	which	surrounds	and	binds	newly	synthesized	single-stranded	DNA	+	strands	before	they	can	be	converted	to	RF.	This	is	a	vital	step,	as	the	double-stranded	RF	cannot	be	packaged	into	phage.	These	pV/single-strand	complexes	are	then	transported	to	the	cell	membrane,2	where	minor	and	major	coat	capsid	proteins	have	been	embedded.	The	pV/single-strand	complex	is	oriented	such	that	the	DNA	begins	to	protrude	from	the	cell.	At	this	point,	pV	binding	proteins	release,	and	are	replaced	by	the	capsid	proteins.	As	the	final	capsid	proteins	are	assembled	onto	the	new	phage,	the	replication	process	of	the	phage	terminates,	and	the	newly	synthesized	phage	particle	is	released	from	the	host	cell.		
A.2. Display	Proteins	Display	on	phage	is	achieved	via	fusion	of	the	gene	encoding	the	protein	of	interest	to	phage	protein	genes.	The	most	commonly	used	coat	proteins	used	for	phage	display	are	pVIII	and	pIII.	pVIII,	the	protein	that	composes	the	phage	cylinder,	is	used	less	frequently	than	pIII.	Two	factors	contributing	to	this	are:	the	protein	can	only	display	short	sequences	of	(6-8)	residues	(longer	sequences	can	prevent	the	packaging	of	phage	molecules,	likely	due	to	interactions	with	pIV),2	and	the	protein	will	display	on	all	copies	of	pVIII	in	a	phage	(this	can	cause	avidity	effects	with	multiple	binding	interactions	and	make	it	difficult	to	accurately	characterize	function	of	the	protein	of	interest).	There	is	a	limitation	to	the	use	of	pVIII;	a	requirement	of	short	sequences	
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reduces	the	number	of	target	peptides	that	can	be	analyzed.	Recent	work	has	extended	the	applicability	of	pVIII	phage	display.	pVIII	proteins	have	been	engineered	to	display	large	polypeptides	at	numbers	sufficient	enough	to	produce	an	100-fold	improvement	in	detection	of	fusion	proteins.16	Other	work	has	developed	successful	fusion	of	proteins	of	interest	to	an	artificial	major	coat	protein	(pVIII	mimic)	at	the	C-terminus	which	expands	the	range	of	proteins	that	can	be	displayed	on	pVIII	(as	opposed	to	the	N-terminus,	which	is	generally	the	location	of	insertion	on	pVIII).17	The	common	site	of	insertion	for	proteins	of	interest	is	the	pIII	gene.5	This	gene	codes	for	the	expression	of	five	copies	of	pIII	on	the	end	of	the	virion.	Unlike	pVIII,	pIII	can	tolerate	large	insertions	while	retaining	the	phage’s	infectivity.2	pIII	is	made	up	of	three	domains	(N1,	N2,	and	CT),	and	two	glycine-rich	linker	regions.	The	N	domains	are	located	in	the	exposed	N-terminal,	and	serve	as	contact	points	for	interaction	between	the	phage	and	ligands.	The	CT	domain	is	located	in	the	C-terminal,	which	is	buried	in	the	phage,	and	is	linked	to	the	assembly	of	the	virus.2	The	protein	of	interest	can	be	inserted	into	the	pIII	gene	at	the	end	of	the	N2	domain	(residue	198)	or	to	the	glycine-rich	linker	region	that	is	near	the	CT	domain	(residue	249).	Both	fusion	locations	have	successfully	displayed	proteins	on	pIII	in	filamentous	phage.18,19		
A.3. Phage	Library	Construction	
A.3.1. Phage	Vectors	Once	a	display	protein	has	been	chosen	as	the	fusion	site	for	a	protein	of	interest,	it	must	then	be	cloned	into	the	gene	and	incorporated	into	the	phage	genome	for	display.	This	is	accomplished	with	a	display	vector.	Some	vectors	are	commercially	available,	and	are	ready	for	use	in	various	experiments.	For	other	proteins,	however,	
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that	have	not	been	displayed	on	phage,	a	vector	must	be	constructed	and	its	functionality	must	be	tested.	Two	major	factors	in	display	vector	construction	are	vector	type,	and	valency.1,2	Display	vectors	are	predominately	of	two	forms:	phage	vectors	and	phagemid	vectors	(Figure	5).1,2,20	Valency	refers	to	the	number	of	foreign	proteins	that	a	phage	displays.21	Multivalent,	or	polyvalent,	phage	are	those	that	display	more	than	one	copy	of	the	foreign	protein	of	interest	per	phage	particle.	Monovalent	phage	predominately	display	one	protein	of	interest	per	phage	particle.	Confirmation	of	display	on	phage	is	the	final	step	in	the	construction	of	a	vector.	Vectors	must	successfully	be	able	to	facilitate	display	of	the	protein	of	interest,	such	that	it	is	both	displayed	and	functional.	
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Figure 5. Comparison of phage and phagemid vector cloning for pIII display. Target 
protein sequences are inserted before gene III. Both vector methods carry a phage 
replication origin (Ff) to permit phage genome replication. Phagemid vectors also 
carry a plasmid origin of replication, and an antibiotic resistance marker. Helper 
phage facilitates viral protein expression, but is packaging-deficient and does not 
compete with the phagemid genome during assembly. In this experiment, 
monovalent phage display is preferred as it reduces the avidity effects that plague 
polyvalent display. Image adapted from Ref. 2.  
 
A.3.1.a. Phage	and	Phagemid	Vectors	Proteins	displayed	using	vectors	based	directly	within	the	Ff	phage	sequence	–	those	incorporated	directly	into	the	coding	sequence	for	either	pIII	or	pVIII	–	are	considered	phage	vectors.	Phage	vectors	typically	result	in	the	display	of	the	protein	of	interest	on	all	copies	of	the	coat	protein,	and,	thus,	are	only	used	in	polyvalent	display.3,22	This	phage	vector	display	method	has	been	used	to	analyze	small	peptides,23–25	and	even	functional	enzymes.26	Polyvalent	display,	however,	features	some	drawbacks.	Polyvalent	display	prevents	the	identification	of	high-affinity	clones.18,24	The	use	of	polyvalent	phage	display	to	analyze	the	binding	affinity	of	peptide	libraries	to	a	(beta)-endorphin	antibody	recovered	sequences	that	were	weakly	binding	relative	to	the	original	starting	sequence.24	Similarly,	attempts	to	use	polyvalent	phage	display	to	select	for	high-affinity	mutants	of	human	growth	hormone	(hGH)	from	among	a	library	of	mutants	with	large	binding	affinity	variations	(over	20-fold)	were	unsuccessful.18	These	studies	found	that	polyvalent	phage	display	results	in	multi-point	attachment	to	ligands	during	selection,	as	a	result	of	the	number	and	proximity	of	displayed	proteins	of	interest.2,18,24	This	multi-point	attachment,	thus,	makes	weak-binding	clones	appear	as	if	they	have	high	affinity,	an	effect	known	as	avidity	(the	strength	of	a	receptor-ligand	complex	of	N	receptor-ligand	interactions).2	Additionally,	
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phage	vector	display	is	complicated	by	the	difficulty	of	cloning	directly	within	the	phage	genome	without	disrupting	important	promoters,	genes,	or	other	genome	structural	components.2	For	these	reasons,	monovalent	phage	display	is	preferred	for	experiments	seeking	to	select	mutants	with	the	highest	affinities.2	Monovalent	display	was	developed	to	account	for,	and	avoid,	potential	avidity	effects	associated	with	polyvalent	display.18,19	Phagemid	vector	display	has	been	shown	to	produce	monovalent	display	phages	that	can	be	used	to	sort	between	low-	and	high-affinity	mutants.18,19	Phagemid	vector	display,	unlike	phage	vector	display,	does	not	feature	the	introduction	of	the	gene	of	interest	directly	into	the	phage	genome.	The	displayed	protein	gene	is,	instead,	fused	to	the	pIII	or	pVIII	genes	in	a	plasmid	under	the	control	of	a	weak	promoter.2,22	The	plasmid	typically	contains:	a	plasmid	origin,	a	phage	replication	origin	(Ff	origin),	and	an	antibiotic	resistance	marker.	Thus,	this	plasmid	contains	the	sequence	necessary	for	the	production	of	the	pIII-protein	fusion	and	for	packaging	of	single	stranded	vector	into	phage	particles,	but	is	incapable	of	encoding	viral	genes.18	Thus,	the	phagemid	vector	technique	requires	the	infection	of	E.	coli	containing	the	phagemid	with	helper	phage	that	is	packaging-deficient,	it	has	a	compromised	Ff	origin.1,2	The	helper	phage	introduces	the	genome	necessary	for	the	cell	to	express	the	viral	proteins	necessary	for	phage	replication.	Because	the	cells	will	express	all	of	the	wild-type	proteins	and	the	fusion	protein	encoded	in	the	phagemid,	the	extruded	phage	particles	will	contain	both	proteins.2	Additionally,	the	deficient	packaging	of	the	helper	phage	genome	ensures	that	most	of	the	phage	particles	will	contain	the	more	stable	phagemid	genome,	thus	preserving	the	genotype-phenotype	link.2	Typically,	the	wild-type	proteins,	including	wild-type	pIII,	will	be	expressed	in	
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excess	relative	to	the	fusion	protein.	This	results	in	<10%	of	the	phagemid	particles	displaying	only	one	copy	of	the	pIII-fusion	protein,	<1%	displaying	two	copies,	and	the	rest	of	the	particles	displaying	solely	wild-type	pIII.1,2,22	The	phage	particles	displaying	only	wild-type	proteins	will	be	eluted	during	selection,	and,	therefore,	do	not	affect	selection	for	binding	affinity.2,22	Similarly,	the	small	percentage	of	phage	particles	that	display	two	copies	of	pIII-fusion	protein	is	statistically	insignificant	upon	multiple	rounds	of	selection.22	Not	only	does	monovalent	display,	and,	as	an	extension,	phagemid	vector	construction	mitigate	any	potential	avidity	effects,	they	also	feature	additional	advantages.22	The	first	advantage	of	monovalent	display	is	the	conservation	of	phage	infectivity.	The	majority	of	pIII	proteins	on	phagemid	constructed	phage	are	wild-type,	thus	these	phage	are	able	to	infect	host	cells	with	nearly	identical	rates	to	wild-type	phage.22	Polyvalent	display	of	pIII	proteins,	on	the	other	hand,	results	in	display	phage	that	are	less	infective	than	wild-type	phage.22	Another	major	advantage	of	phagemid	display	vectors	is	that	they	can	be	used	to	also	freely	express	the	protein	of	interest	for	biochemical	analysis	and	sequencing.2,22	The	addition	of	an	amber	stop	codon	(TAG)	between	the	inserted	gene	and	the	pIII	gene	in	the	phagemid	facilitates	the	controlled	free	expression	of	the	protein	of	interest.19	Expression	of	vectors	containing	the	amber	stop	codon	within	E.	Coli	strains	that	suppress	the	stop	codon,	amber-suppressors,	allows	for	protein	translation	through	the	stop	codon,	resulting	in	pIII-fusion	proteins.2,22	Vectors	of	interest	(ones	that	have	gone	through	a	selection	process,	perhaps)	can	then	be	transformed	into	non-suppressor	E.	
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Coli	strains,	resulting	in	the	expression	of	the	protein	of	interest	(not	fused	to	pIII).2,22	This	method	has	been	used	to	effectively	display	and	express	high	levels	of	non-phage-linked	Fabs	and	hGH	without	additional	phage	genome	manipulation.19,27	
A.3.1.b. Vector	Display	Confirmation	Confirmation	that	a	newly	constructed	phagemid	vector,	or	phage	vector,	actually	displays	the	protein	of	interest	is	vital.	Phage	enzyme-linked	immunosorbent	assays	(ELISA)	is	a	successful	method	for	establishing	the	functional	display	of	a	protein	on	phage.	In	the	case	that	display	cannot	be	confirmed,	modifications	to	the	fusion	gene,	vector	type,	or	display	protein	used	must	be	considered.2	
A.3.2. Library	Construction	Once	a	display	vector	has	been	constructed	and	confirmed	for	a	protein,	the	protein	can	then	be	diversified.	Protein	diversification	allows	for	the	analysis	of	effects	that	various	mutations	have	on	protein	folding,	structure,	and	activity.	Libraries	with	diversities	of	approximately	1010	are	reasonably	constructed,28,29	with	some	methods	reaching	even	larger	orders	of	magnitude.	Diversification	can	aim	for	complete	randomization,	allowing	for	mutations	among	all	amino	acids	and	across	the	entire	gene	sequence.	Other	diversification	methods	can	produce	biased	or	incomplete	mutant	libraries,	which	can	be	composed	of	specific	amino	acid	subsets	or	limited	to	specific	locations	within	the	gene	sequence.		Regardless	of	which	library	construction	method	is	used,	the	ability	to	create	large	libraries	of	mutant	proteins	allows	for	the	analysis	of,	and	insight	into,	the	interactions	in	receptor-ligand	complexes.	Phage	display	is	a	valuable	protein	engineering	tool	as	it	allows	for	successful	evaluation	of	a	large	library	of	protein	
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variants,	in	the	range	of	108,	as	previously	discussed.	Traditional	screening	methods	are	unable	to	evaluate	nearly	as	many	variants,	typically	limited	to	10-100,	due	to	time	and	material	constraints.	
A.3.2.a. Oligonucleotide-directed	Mutagenesis	Site-directed	mutagenesis	specifies	mutation	locations	within	a	gene	sequence,	as	opposed	to	completely	random	diversification.	This	method	of	mutagenesis	features	the	replacement	of	specific	codons	in	the	gene	sequence	with	degenerate	codons	that	can	encode	for	more	than	one	amino	acid.28	These	degenerate	codons	are	made	up	of	mixtures	of	nucleotides	at	different	positions	in	the	codon’s	three-nucleotide	sequence.	For	example,	the	codon	NNS	is	able	to	encode	for	all	amino	acids	(where	N	=	any	nucleotide,	and	S	=	C	or	G).30	Because	site-directed	diversification	requires	the	use	of	synthetic	DNA,	and	synthetic	DNA	composition	can	be	altered,	facile	control	of	diversity	is	achievable.	For	example,	alteration	of	the	design	of	the	degenerate	codons	will	dictate	the	focus	and	breadth	of	the	library’s	diversity.	For	complete	diversification	of	a	sequence,	hard	randomization,	the	use	of	degenerate	codons	that	encode	for	all	amino	acids,	is	used.	Alternatively,	tailored	randomization	restricts	the	degenerate	codons	to	those,	which	only	encode	for	specific	amino	acid	subsets.	Lastly,	soft	randomization,	a	more	restrictive	model,	limits	degenerate	codon	variation	and	biases	the	mutations	to	a	predetermined	sequence.28		Oligonucleotide-directed	mutagenesis	is	a	simple	method	for	constructing	site-directed	mutant	libraries	as	described	in	Figure	6.28	The	method	can	be	utilized	to	conduct	hard	randomization,	tailored	randomization,	or	soft	randomization.	The	general	scheme	for	oligonucleotide-directed	mutagenesis	remains	follows	the	same	
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general	protocol,	regardless	of	the	type	of	degenerate	codon	design.28	A	template	plasmid,	containing	the	gene	of	interest,	is	first	prepared	for	diversification.	Transformation	of	the	template	plasmid	into	an	E.	Coli	dut	–/ung	–	strain,	like	CJ236,31	purifies	the	plasmid	into	a	single-stranded	form	that	has	a	significant	amount	of	thymine	bases	replaced	by	uracil.28	The	synthetically	designed	oligonucleotide,	containing	the	desired	mutations,	then	anneals	to	bases	preceding	and	following	the	desired	mutation	region.	This	oligonucleotide	then	serves	as	a	primer	for	a	DNA	polymerase,	which	replicates	a	complementary	strand	to	the	template	plasmid.	A	DNA	ligase	then	ligates	the	replicated	strand	into	a	circular,	double-stranded	DNA.	The	resulting	double-stranded	DNA	is	not	entirely	complementary;	the	oligonucleotide	region	containing	the	mutation	does	not	match	the	template.	The	introduction	of	the	double-stranded	DNA	into	an	E.	Coli	ung	–	strain	results	in	the	preferential	replication	of	the	new	mutagenic	DNA	strand.28,31,32	The	higher	the	purity	of	a	template,	the	more	efficient	the	oligonucleotide	mutagenesis	is.	Efficiency	can	range	from	>50%,	to	>80%	depending	on	template	purity.28	
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Figure 6. Schematic displaying oligonucleotide-directed mutagenesis. a) A synthetic 
oligonucleotide is annealed to a single-stranded DNA template that has a significant 
amount of thymine bases replaced by uracil (ss-DNA). The oligonucleotide contains 
a degenerate codon, and is designed to encode mutations (*). b) A double-stranded 
DNA (CCC-dsDNA) is synthesized by polymerase and ligase. c) The CCC-dsDNA is 
then transformed into E. coli cells where it is replicated to either the mutant or wild-
type sequence. Image adapted from Ref. 28. 
 A	major	limitation	of	oligonucleotide	mutagenesis	is	the	fact	that	it	is	far	from	100%	efficient,	meaning	that	libraries	constructed	using	this	method	will	contain	wild-type	proteins.	In	cases	where	the	wild-type	protein	exhibits	high	affinity	for	binding	to	the	target,	the	wild-type	proteins	displayed	on	phage	will	be	selected	for	alongside	mutant	proteins.28	Thus,	it	is	imperative	that	mutant	libraries	constructed	via	oligonucleotide	mutagenesis	are	purified	of	the	wild-type	protein.	This	can	be	accomplished	by	rendering	the	template	inactive.	An	inactive	template	permits	the	construction	of	mutant	libraries,	retaining	the	functionality	required	for	oligonucleotides	to	bind	to	the	template	strand,	but	does	not	allow	for	the	expression	of	the	wild-type	protein	encoded	in	the	template.	The	incorporation	of	stop	codons	within	the	desired	mutated	region	of	the	template	sequence	achieves	this.28,33	Translation	of	
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the	stop	codon	incorporated	template	sequence	results	in	truncated	proteins.	Because	they	are	no	longer	translated	as	complete,	pIII-fused	proteins	they	cannot	be	displayed	on	phage.	The	inactive	template	still	serves	as	the	wild-type	genome,	yet	can	no	longer	interfere	with	selection.28	In	general,	templates	that	contain	at	least	one	stop	codon	per	target	region	will	likely	be	rendered	inactive.	
A.3.2.b. In	vitro	DNA	Recombination	Another	robust	library	construction	method	is	the	use	of	in	vitro	DNA	recombination	in	directed	evolution.	Directed	evolution	is	an	in	vitro	simulation	of	natural	Darwinian	evolution.	A	protein	of	interest	is	run	through	iterative	rounds	of	mutation,	selection,	and	screening.	Each	round	is	akin	to	a	generation,	or	another	representative	period	of	time,	as	in	Darwinian	evolution.	This	method	allows	for	the	production	of	mutants	with	specific	properties.34,35			Stemmer	reported	the	first	use	of	In	vitro	DNA	recombination	as	a	method	for	evolution.36,37	DNA	shuffling,	as	Stemmer	called	it,	incorporates	a	low	rate	of	point	mutations	within	recombination	of	related	sequences	of	the	template.34	Other	In	vitro	DNA	recombination	methods	have	followed	Stemmer’s	DNA	shuffling.	These	include	random	priming	recombination,38	and	Staggered	extension	process	(StEP).39	
In	vitro	DNA	recombination	has	proven	successful	in	a	number	of	applications.	Stemmer	initially	utilized	DNA	shuffling	to	improve	drug	resistance.36,37	Others	have	used	the	method	to	improve	and	alter	various	protein	characteristics	and	functions.	The	thermostability	of	enzymes	has	been	generated	and	improved	by	recombination	random	mutagenesis	and	selection.40–42	Additionally,	the	folding	and	solubility	for	single-chain	antibody	fragments,43	and	the	green	fluorescent	protein	were	improved.44	
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While	this	library	construction	method	has	proven	successful	in	the	optimization	and	analysis	of	protein	function,	it	does	feature	drawbacks.	One	of	its	major	limitations	is	a	result	of	the	method’s	logic.	Because	In	vitro	DNA	recombination	requires	that	the	“best,”	or	most	optimized,	sequence	be	selected	and	then	further	mutated,	it	does	not	allow	for	the	discovery	of	other	successful	mutations.	Those	mutants	can	only	be	discovered	in	separate	recombination	experiments;	in	which	they	are	found	to	be	the	“best”	mutant.34	This	is	a	seemingly	small	limitation,	yet	can	result	in	the	loss	of	vital,	or	optimal,	mutant	discoveries.	
A.3.2.c. Other	Methods	Other	methods	for	diversification	of	a	mutant	library	have	been	described.2	These	include	but	are	not	limited	to:	the	oligo	cassette	method,45	recursive	polymerase	chain	reaction	(PCR),46	oligo-splinted	assembly,47	error-prone	PCR,48	and	the	use	of	PCR	with	randomized	primers.49	Other	methods	for	phage	display	library	construction	involve	collections	of	genes,	as	opposed	alterations	to	single	genes	(cDNA	libraries,50	and	antibody	V-region	libraries,51	for	example).	Choosing	a	method	for	a	specific	experiment	depends	on	a	few	factors.	First,	the	type	of	mutagenesis	must	be	considered.	Random	mutagenesis	can	lead	to	novel	function	discoveries,	while	site-directed	mutagenesis	allows	for	the	analysis	of	the	impact	that	specific	positions,	or	mutations	have	on	function.	Second,	the	target	region	for	diversification	must	be	defined	and	considered.	If	the	mutagenesis	of	an	entire	gene	is	desired,	it	will	require	a	different	method	to	mutagenesis	that	aims	to	contain	mutations	within	a	defined	region.	Lastly,	the	efficiency	of	a	method	must	be	weighed	against	its	accuracy,	faster	methods	may	not	necessarily	have	more	accurate	results,	and	vice-versa.	
	 22	
A.3.3. Selection	
A.3.3.a. General	Approach	Once	a	library	of	mutant	proteins	has	been	constructed	and	displayed	on	phage,	the	library	population	must	be	sorted	by	binding	affinity.	This	stage	in	phage	display	is	called	selection,	and	results	in	the	optimization	of	protein	binding	to	a	specific	target.	Generally,	selection	will	allow	for	the	separation	of	tight	binders,	or	“fit”	binders,	from	non-binders	or	weakly	binding	variants.	Consecutive	rounds	of	successful	selection	yields	the	emergence	of	a	single	clone,	or	set	of	clones,	that	have	relatively	optimal	binding	affinities.3,20	
A.3.3.b. Methods	Selection	methods	all	follow	a	general	idea,	the	separation	of	“good”	binders,	those	that	retain	or	have	developed	high	binding	affinity	to	the	target	relative	to	a	standard	like	wild-type	affinity,	from	non-functional	or	weak	binders.	The	type	of	selection	method,	however,	depends	on	the	mechanism	of	binding	that	is	being	analyzed,	or	optimized.	In	general,	selection	can	be	separated	into	two	methods:	immobilization	of	the	displayed	protein,	or	binding	of	the	protein	within	solution.20	Additionally,	selection	conditions	must	be	stringent	enough	to	allow	for	the	retention	of	fit	mutants	and	the	extraction	of	other	variants	from	the	mutant	pool.	These	conditions	must	also,	however,	allow	for	the	recovery	of	fit	variants	in	order	to	enable	further	selection	rounds	and	final	analysis.20	Therefore,	a	selection	strategy	must	also	facilitate	pairing	with	an	efficient	and	effective	elution	strategy.	
A.3.3.b.1. Immobilization	
	 23	
The	phage	target	can	be	immobilized	onto	a	solid	support,	thus	rendering	the	pIII-fusion	protein	:	target	interaction	immobile.	The	general	mechanism	follows	as	such:	the	target	(protein,	molecule,	ligand,	etc.)	is	covalently	attached	to	the	solid	support,	then	the	phage	library,	in	the	presence	of	buffer,	is	introduced	into	the	system	inducing	interaction,	and	finally	the	mutant	variants	that	do	not	bind	are	washed	away	and	those	that	do	are	eluted	for	further	analysis.20	The	solid	state	target	can	select	for	fit	variants	in	one	of	two	ways.	Variants	can	be	selected	for	binding	affinity	to	a	substrate	covalently	attached	to	the	solid	support.	Thus,	only	variants	with	a	relatively	high	binding	affinity	will	remain	in	the	system	after	subsequent	washing.	In	the	case	that	catalysis	optimization	is	the	goal,	another	setup	can	be	utilized.	All	variants	can	be	attached	to	the	solid	support,	where	they	are	introduced	to	a	substrate,	and	then	catalysis	can	result	in	cleavage	of	fit	variants	from	the	solid	support.	Upon	which	washing	of	the	system	would	elute	fit	variants,	while	less-fit	variants	remain	attached	to	the	support.5		Elution	of	directly	immobilized	phage	typically	follows	one	of	two	general	schemes.	In	the	situation	where	selection	conditions	are	designed	to	immobilize	phage	based	on	binding	affinity	to	the	solid	support,	elution	aims	to	dissociate	the	phage	from	the	binding	target,	or	to	dissociate	the	target,	with	the	attached	phage,	from	the	stable	support	itself.20	Phage	dissociation	from	target	can	be	induced	by	alteration	of	pH	levels	to	extremes	or	addition	of	denaturants;	phage	infectivity	can	be	retained	after	exposure	to	extreme	conditions.2	Alternatively,	binding	targets	can	be	covalently	attached	to	solid	supports	via	specific	tags,	or	engineered	cleavage	sites	(cloning	specific	amino	acid	chains,	or	binding	sites	into	a	protein	is	an	example	of	engineering).	Attachment	to	solid	
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support	can	be	cleaved	at	these	sites	upon	the	incorporation	of	specific	molecules	or	conditions.	For	example,	thrombin	can	be	added	to	a	solution	to	cleave	an	engineered	thrombin	site	on	a	binding	target	protein.20		If	selection	aims	to	optimize	the	catalytic	function	of	a	protein,	as	previously	described,	the	elution	conditions	focus	on	collection	of	catalytically	active	variants.	For	catalytic	processes	that	involve	cleavage,	selection	and	subsequent	elution	can	be	accomplished	by	inhibiting	cleaving	function	during	the	selection	stage,	and	then	inducing	cleavage	as	an	elution	strategy.	Pedersen	et	al.	were	able	to	optimize	the	enzyme	staphylococcal	nuclease	(SNase)	for	the	catalysis	of	DNA	cleavage	by	utilizing	the	immobilization	method,	and	eluting	variants	that	had	successfully	cleaved	from	the	solid	support.5	The	activity	of	the	nuclease	was	inhibited	by	control	of	Ca2+	levels;	SNase	does	not	cleave	its	substrate	in	the	absence	of	Ca2+.	Following	selection,	elution	was	accomplished	through	the	introduction	of	Ca2+,	which	detached	fit	variants	from	the	solid	support	by	inducing	cleavage.	
A.3.3.b.2. Solution	Binding	Phage	library	variants	can	also	be	selected	via	binding	in	a	solution	and	subsequent	capture	by	a	solid	support	(i.e.	an	affinity	matrix).	This	method	can	reduce	the	potential	avidity	effects	of	polyvalent	phage,	because	interaction	with	a	target	in	solution	does	not	have	the	same	intramolecular	effects	as	binding	to	targets	on	a	solid	support.20	On	a	solid	support,	as	previously	discussed,	a	polyvalent	phage	will	initially	bind	to	a	single	target,	but	will	undergo	multiple	binding	events	as	a	result	of	target	proximity	the	multiple	displayed	proteins	present	on	a	polyvalent	phage	particle.	Solution	binding	can	still	facilitate	multiple	binding	events,	however,	the	likelihood	of	
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these	subsequent	binding	events	is	not	increased	to	the	degree	that	binding	on	a	surface	does.	This	is	because	each	target	molecule	is	independent,	and	binding	does	not	inherently	bring	the	phage	closer	to	other	targets.		Elution	strategies	for	solution	bound	phage	are	similar	to	those	for	phage	selected	with	the	immobilization	strategy.	Generally,	elution	strategies	aim	to	break	the	link	between	the	phage	and	the	binding	target,	or	the	affinity	matrix.	The	introduction	of	basic	or	acidic	conditions,	at	levels	that	the	phage	can	tolerate	(which	are	typically	extreme	for	most	other	molecules	or	organisms),	is	a	typical	technique	for	accomplishing	this.	For	example,	hydrochloric	acid	(HCl)	and	triethylamine	are	typical	reagents.2	
A.3.3.b.3. Selection	Conditions	The	first	round	of	selection,	typically,	segregates	functional	variants	from	non-functional	variants.20	This	initial	step	is	focused	on	producing	a	resultant	library	that	is	diverse,	but	contains	only	functional	variants.	Further	rounds	of	selection	aim	to	obtain	the	variants	with	the	highest	levels	of	function.	Thus,	the	stringency	of	selection	conditions	will	increase	to	remove	low	affinity	variants.	Methods	for	increasing	stringency	include	longer	washing	times,	increased	number	of	washings,	the	addition	of	denaturants,52	increased	temperatures	or	the	addition	of	competitive	binders	or	ligands.53	The	increased	stringency	results	in	the	selection	of	more	and	more	optimal	variants,	with	the	final	selection	aimed	at	isolating	the	“best”	variant	from	a	specific	library.	
B. High-throughput	Sequencing.	
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While	phage	display	is	an	effective	and	efficient	method	for	selecting	protein	variants	with	specific	functions	and	affinities,	it	does	not	address	the	issues	associated	with	the	analysis	of	the	selected	variants.	Traditionally,	mutational	analysis	was	the	primary	method	with	which	mutant	variants	of	a	protein	were	examined.	Traditional	scanning	of	mutants	does	have	its	drawbacks.4	Originally,	mutants	were	cloned,	expressed,	and	purified	in	preparation	for	assays	and	further	analysis.	Phage	display,	a	method	which	directly	and	accurately	links	phenotype	to	genotype,	reduces	the	need	for	purification	of	individual	protein	variants.4	The	requirements	of	Sanger	sequencing,	however,	still	restricted	the	number	of	total	variants	that	could	be	analyzed	to	a	few	thousand.	Recent	work	in	high-throughput	sequencing,	such	as	combinatorial	scanning,54	and	short-read	Illumina	sequencing,4	has	substantially	expanded	the	volume	of	variants	that	can	be	assessed	and	sequenced	in	a	reasonable	period	of	time.55–57	For	example,	combinatorial	“quantitative	saturation	(QS)	scanning”	enabled	effective	and	efficient	assessment	of	the	interaction	between	human	growth	hormone	(hGH)	and	its	receptor	(hGHR).54	High-throughput	sequencing,	coupled	with	phage	display	selection	can	be	used	to	map	resistance	of	protein	mutants	to	antibiotics	or	anticancer	drugs.	
B.1. Short	Read	Illumina	sequencing		 The	principle	behind	Illumina’s	high-throughput	sequencing	method	is	that	a	DNA	template	strand	is	broken	into	smaller	fragments,	and	then	the	bases	of	those	fragments	are	identified	as	each	section	of	the	entire	sequence	is	re-synthesized	as	described	in	Figure	7.	The	DNA	to	be	sequenced	is	extracted	and	then	fragmented	into	a	collection	of	short	segments.	These	segments	are	then	simultaneously	sequenced	via	
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Illumina’s	sequencing	reactions.	The	resulting	sequences,	or	reads,	are	then	reassembled	in	comparison	to	a	reference	genome.	In	the	case	that	a	reference	genome	is	unavailable,	or	does	not	exist,	the	segments	can	be	reassembled	via	de	novo	sequencing	methods.58,59	
	
Figure 7. Illumina high throughput sequencing scheme. 1) Multiple DNA sequences 
are extracted from selected phage. 2) Sequences are fragmented. 3) Each set of 
fragments is labelled with a tag. 4) Fragments are simultaneously sequenced. 5) 
Fragments separated by tag. 6) Each set of sequencing reads is compared to a 
reference sequence. 
 	 High-throughput	sequencing	of	an	entire	library	of	DNA	(genomes	extracted	from	a	phage	display	library,	for	example)	can	be	similarly	sequenced.	The	above	method	is	simply	run	in	parallel	for	each	sequence	of	interest.	This	is	accomplished	by	
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attaching	a	specific	known	barcode	sequence	to	each	DNA	fragment	originating	from	a	specific	original	sequence.	The	fragments	are	all	pooled	and	sequenced	simultaneously,	and	the	barcode	sequences	are	used	to	distinguish	fragments.	Each	set	of	fragments	is	then	reassembled,	based	on	a	reference	genome	or	via	de	novo	sequencing.	This	sequencing	technique	can	produce	large	amounts	of	sequencing	data,	with	small,	measurable	margins	of	error.4,58,59	
B.2. Application	and	Results	Fowler	et	al.	used	high-throughput	sequencing	to	successfully	investigate	the	binding	of	the	human	Yes-associated	protein	65	(hYAP65)	WW	domain	to	its	cognate	peptide	ligand	for	upwards	of	600,000	hYAP65	mutants.4	The	hYAP65	WW	domain	was	displayed	on	the	surface	of	T7	bacteriophage,	and	mutant	variants	were	selected	for	binding	affinity	to	the	cognate	peptide,	attached	to	a	solid	support	via	beads.	The	WW	domain	library	varied,	or	mutated,	33	residues	within	the	domain,	and	consisted	of	99	varied	bases.	The	input	variant	library,	and	the	libraries	after	three	and	six	rounds	of	selection	were	sequenced	via	short-read	Illumina	sequencing.	The	sequence	data	was	then	used	to	map	and	compare	the	three	libraries,	highlighting	the	relative	abundances	of	mutations	at	specific	locations	through	six	rounds	of	selection	(Figure	8).		
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Figure 8. Sample high throughput 
sequencing maps. Maps display the 
frequency of reads of a specific amino 
acid mutation at a specific position in 
the target protein for the variant library 
after zero (initial library), three, and six 
three rounds of selection, respectively. 
Image adapted from Ref. 4.		
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 Through	the	use	of	high-throughput	sequencing,	coupled	with	phage	display,	Fowler	et	al.	were	able	make	conclusions	about	mutations	at	specific	positions	within	the	sequence	that	improved	protein	function.	More	importantly,	the	mapping	of	sequences	obtained	via	high-throughput	sequencing	could	be	used	to	identify	positions	within	a	gene	that	are	vital	for	protein	function,	structure,	or	folding.4	
C. RAS	Oncogene	
C.1. RAS	Structure/Function	Four	distinct,	yet	very	homologous,	RAS	proteins	are	encoded	for	in	the	human	genome.	The	HRAS,	NRAS,	and	KRAS	genes	encode	HRAS,	NRAS,	KRAS4A,	and	KRAS4B.60	RAS	proteins	are	small-GTPase	membrane	bound	proteins,	~21	kDa,	that	are	primarily	associated	with	signal	transmission	in	cells	by	pairing	cell	surface	receptors	with	intracellular	signaling	pathways.1,47	They	cycle	between	active,	GTP-bound,	and	inactive,	GDP-bound,	states;	acting	as	ON/OFF	switches	for	cell	growth,	differentiation	and	growth.61	Guanine	nucleotide	exchange	factors	(GEFs),	which	can	facilitate	the	exchange	of	GDP	for	GTP	on	GTPase	proteins,	activate	RAS	by	promoting	the	GTP-bound	state.60,62	On	the	other	hand,	GTPase-activating	proteins	(GAPs),	which	accelerate	the	hydrolysis	of	GTP	into	GDP,	promote	the	formation	of	the	inactive,	GDP-bound,	state.60,62	This	GAP	mediated	inactivation	of	RAS	is	the	main	target	of	somatic	mutations	found	in	oncogenic	RAS	variants.60	Mutations	in	RAS	at	amino	acid	positions	G12,	G13,	or	Q61	interfere	with	the	ability	of	GAP	to	inactivate	GTP-bound	RAS.	In	the	presence	of	any	of	these	mutations,	activated	RAS	will	persist	within	the	cell	where	it	will	signal	through	various	pathways	facilitating	the	transformation	of	mammalian	cells.60,62	
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RAS	carries	signals	to	these	pathways	by	binding	proteins,	or	other	ligands,	at	the	effector	domain.	Binding	at	this	domain,	spanning	residues	32-40,	is	essential	for	signal	transduction.62	It	has	been	shown	that	mutations	in,	or	near,	this	region	impair	interaction	between	RAS	and	its	binding	partners.63	RAS	has	specific	binding	interactions	at	the	RAS	effector	domain	with	a	number	of	RAS	effectors,	such	as:	phosphatidylinositol	3-kinase	(PI3K),64	p120	RAS	GAP,65	and	RIN1.66	
C.2. Oncogenic	RAS		 RAS	genes	have	been	found	to	have	oncogenic	function	via	point	mutations	(at	amino	acid	positions	12,	13	and	61,	for	example),67	and	that	these	mutations	occur	in	30%	of	human	cancers.62,68	Thus,	it	has	been	found	that	RAS	proteins	are	the	most	commonly	mutated	oncogene	in	human	cancer.61	For	this	reason,	inhibition	of	RAS	oncogenic	activation	has	major	implications	in	cancer	therapy.		 The	oncogenic	activity	of	the	four	RAS	isoforms	(HRAS,	NRAS,	KRAS4A,	and	KRAS4B)	has	not	been	completely	determined,	nor	has	the	issue	of	whether	some	isoforms	exhibit	unique	activity	been	resolved.	On	one	hand,	the	isoforms	follow	a	non-random	distribution	within	the	range	of	known	cancer	types.69,70	Mutations	in	HRAS	are	frequently	detected	in	skin,	head,	and	neck	tumors.	KRAS	mutations	are	associated	with	colorectal	tumors,	and	lung	and	pancreatic	carcinomas.	Lastly,	NRAS	mutations	are	typically	found	haematopoietic	and	lymphoid	tissue	tumors.60	On	the	other	hand,	RAS	isoforms	can	substitute	other	isoforms	within	specific	tissues,	where	they	perform	the	same	function	as	the	oncogenic	RAS	isoform	typically	associated	with	that	specific	tissue.60,71	Aberrations	from	this	trend	have	been	discovered;	especially	when	RAS	
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isoforms	are	analyzed	in	vivo.	Thus,	it	has	been	difficult	to	determine	the	exact	mechanisms	and	interactions	that	oncogenic	isoforms	have	within	the	cell	cycle.		 Independent	of	RAS	isoform	variations,	oncogenic	RAS	has	phenotypic	effects	across	a	wide	range	of	typical	cell	functions.	In	fact,	the	contribution	of	oncogenic	RAS	to	human	malignancies	is	typically	underestimated	by	the	frequency	of	RAS	mutations	found	in	cancer	types.60	Mutations	in	RAS	have	a	wide	impact	on	cancer	function,	and	the	growth	and	spread	of	cancer.	Oncogenic	RAS	can	affect	the	promotion	of	cell	proliferation,	the	suppression	of	cell	apoptosis,	metabolism,	the	cell	microenvironment,	immune	response	evasion,	and	metastasis	(Figure	9).	All	of	these	are	vital	mechanisms,	functions,	or	components	of	cells.	Alterations	in	any	of	them	can	induce	cancer,	or	tumor	growth.	
	 33	
	
Figure 9. Cancer-related impacts of oncogenic RAS. Table 
adapted from Ref. 60.  
 
C.2.1. Cell	Proliferation	A	common	characteristic	attributed	to	carcinoma	is	the	continual	expansion	of	cancer	cells;	that	is,	the	growth	of	cell	population	via	uncontrolled,	or	atypical,	cell	division.	Cell	proliferation	depends	on	the	interference	of	appropriate	cell	response	to	mitogenic,	and	anti-mitogenic,	cell	signals.60	Since	RAS	is	directly	involved	in	the	transmission	of	mitogenic	signals	within	a	cell,	oncogenic	RAS	is	able	to	promote	cell	proliferation	via	a	number	of	mechanisms.	The	expression	of	oncogenic	HRAS	has	been	discovered	to	push	a	GO	phase-arrested	cell,	a	cell	that	is	in	a	non-dividing	equilibrium	state,	toward	cell	division	without	stimulus	from	cell	growth	factors.72		
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Additionally,	RAS	oncogenes	can	facilitate	cell	proliferation	by	signaling	for	the	upregulation	of	various	transcription	factors,	such	as:	FOS,	activating	transcription	factor	2	(ATF2),	JUN	(leucine	zipper	protein,	and	ELK1.60	The	main	mechanism	in	which	oncogenic	RAS	mediated	upregulation	of	transcription	factors	leads	to	cell	transformation	is	the	expression	of	cyclin	D1,	the	G1	cyclin;	a	regulator	of	cell	cycle	progression	and	a	transcription	co-regulator.	This	mechanism	is	validated	by	the	fact	that	mice	lacking	cyclin-D1	have	been	found	to	exhibit	resistance	to	carcinomas	and	tumors	that	are	promoted	by	oncogenic	HRAS.73,74	There	are	other	ways	in	which	oncogenic	RAS	can	affect	cell	proliferation	via	the	upregulation	of	pathways	that	lead	to	cell	division	(or	other	cellular	pathways	that	affect	such	pathways)	or	the	downregulation	of	factors	involved	with	the	inhibition	of	cell	growth.	Overall,	due	to	the	massive	role	that	RAS	plays	in	the	regulation	of	cell	population	it	is	not	surprising	that	RAS	oncogenes	have	been	found	in	a	wide	range	of	cancers.		
C.2.2. Cell	Apoptosis	The	elimination	of,	or	interference	with,	signaling	pathways	that	induce	cell	apoptosis	is	a	major	characteristic	of	cancer,	and	the	spread	of	cancer	cells.	Apoptosis	is	a	programmed	process	of	cell	death	that	can	be	initiated	by	extracellular	or	intracellular	factors.	Typically,	apoptosis	is	a	response	to	high	levels	of	cellular	stress,	and	acts	as	a	defense	mechanism	against	malignancies.60	Oncogenic	RAS	erodes	apoptotic	pathways	via	the	upregulation	of	anti-apoptotic	factors	and	downregulation	of	pro-apoptotic	factors.	Chin	et	al.	discovered	that	the	RAS	oncogene	not	only	arrests	cellular	apoptosis	pathways,	but	is	also	important	for	tumor	
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maintenance.75	The	downregulation	of	oncogenic	HRASG12V	lead	to	tumor	cell	apoptosis,	and	subsequent	regression	of	melanomas.75	Similarly,	the	removal	of	oncogenic	KRASG12D	also	caused	tumor	cell	apoptosis,	accompanied	by	the	regression	of	lesions	and	malignant	tumors.76	
C.2.3. Metabolism	As	RAS	oncogenes	induce	high	levels	of	cell	proliferation,	accompanied	by	the	erosion	of	apoptotic	pathways,	the	need	for	cellular	building	blocks	increases	to	accommodate	the	increased	rates	of	growth.	In	order	to	proliferate,	a	cell	must	accomplish	two	tasks.	It	must	generate	sufficient	energy	and	produce	biomolecules	at	a	rate	that	meets	proliferation	demands.77	Thus,	cancer	is	dependent	on	metabolic	pathways	as	they	provide	the	components	needed	for	the	construction	of	new	cells,	and	provide	mechanisms	for	energy	production.		 In	order	to	meet	these	needs	of	proliferation,	cancerous	cells	will	shift	from	mitochondrial	oxidative	phosphorylation	(OXPHOS)	to	aerobic	glycolysis.60	Glycolysis	in	typical	mammalian	cells	is	inhibited	by	the	presence	of	oxygen,	which	is	used	by	the	mitochondria	to	oxidize	pyruvate	to	carbon	dioxide	and	water.	Aerobic	glycolysis	instead,	converts	pyruvate	to	lactate.78	This	mechanism	allows	the	cell	to	recover	the	NAD+	required	for	the	cycle	repeat.77	This	self-sustaining	cycle	can	produce	more	ATP,	and	at	a	faster	rate,	than	OXPHOS,	while	also	providing	metabolic	intermediates	that	can	be	used	for	the	production	of	biomolecules	required	for	cell	proliferation.		 Oncogenic	RAS	facilitates	aerobic	glycolysis	through	numerous	pathways.	First,	oncogenic	RAS	stimulates	the	shift	from	OXPHOS	to	glycolysis	in	cells	via	the	upregulation	of	hypoxia-inducible	factor	1α.60	Additionally,	oncogenic	RAS	improves	a	
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cells	ability	to	transport	the	glucose	necessary	for	glycolysis	by	upregulating	the	glucose	transporter	GLUT1.60	Lastly,	oncogenic	RAS	affects	the	synthesis	of	biomolecules	by	increasing	the	levels	of	enzymes	associated	with	the	processing	of	glycolytic	intermediates.	Hence,	RAS	oncogenes	play	a	critical	role	in	the	cancer-characteristic	metabolic	shift	that	cells	undergo.		
C.2.4. Cell	Microenvironment	As	the	number	of	cells	in	a	tumor	growth	increases,	the	competition	for	oxygen	and	nutrients	among	cells	also	increases.	Angiogenesis	is	the	growth	of	new	blood	vessels	from	pre-existing	blood	vessels.	Angiogenesis	within	a	tumor	allows	for	the	delivery	of	adequate	supplies	of	oxygen,	among	other	nutrients,	to	sustain	tumor	growth.60	Oncogenic	RAS	reaches	beyond	the	confines	of	the	cell	membrane	to	impact	the	extracellular	microenvironment,	and	induce	angiogenesis.	It	accomplishes	this	by	upregulating	angiogenic	growth	factors	and	by	changing	the	composition	of	the	extracellular	matrix,	the	system	of	biological	molecules	that	provide	structural	and	signaling	support	to	cells.60	For	example,	oncogenic	RAS	targets	vascular	endothelial	growth	factor	A	(VEGFA),	a	promoter	of	endothelial	cell	growth	and	the	formation	of	blood	vessels.79	Additionally,	matrix	metalloproteinase	2	(MMP2),	MMP9	and	urokinase-type	plasminogen	activator	(uPA)	are	upregulated	by	RAS	oncogenes,	resulting	in	the	removal	of	physical	constraints	to	angiogenesis.80	The	role	that	oncogenic	RAS	plays	in	the	promotion	of	angiogenesis	indicates	that	RAS	does	not	only	increase	tumor	growth	intracellular,	but	can	also	impact	the	extracellular	environment.		
C.2.5. Evasion	of	Immune	Response	
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Humans	have	mechanisms	within	their	immune	systems	that	can	identify	and	defend	against	cancerous	tumor	growth.	These	immune	responses	are	vital	components	of	the	body’s	defense	against	cancer.	Tumors	that	can	subvert	these	response,	are	able	to	grow	unimpeded	by	antitumor	immunity	pathways,	which	can	lead	to	metastasis.	RAS	oncogenes	can	provide	cells	with	mechanisms	with	which	to	evade	immune	responses	within	the	body.60		Oncogenic	RAS	has	been	found	to	suppress	the	effectiveness	of	the	immune	response	via	two	mechanisms.60	First,	RAS	oncogenes	can	reduce	the	expression	of	antigens	on	cell	surfaces,	thereby	aiding	in	the	cell’s	ability	to	evade	detection	of	lymphocytes.81	Second,	oncogenic	activity	of	RAS	can	actually	overcome	immune	response,	as	opposed	to	evading	them.	For	example,	while	patients	with	some	forms	of	cancers	induced	by	oncogenic	RAS	possess	T-cells	that	are	specific	for	antigens	formed	by	these	RAS	variants,	these	lymphocytes	are	rendered	angenic	and	cannot	actually	bind	the	cancer	cells.60		
C.2.6. Metastasis	Metastasis	is	the	biological	process	in	which	tumor	cells	spread	from	the	organ	of	origin	to	surrounding	organs	and	tissues.	Cancers	in	this	stage	are	difficult	to	treat	due	to	the	mobile	nature	of	the	tumors,	and	the	sheer	number	of	locations	in	which	tumors	are	and	can	be	located.	Many	tumors	that	have	developed	metastatic	properties	contain	oncogenic	RAS	variants.60		Metastasis	is	initiated	by	local	tumor	cell	invasion.	In	order	for	a	tumor	to	enter	this	stage,	individual	tumor	cells	must	develop	the	ability	to	detach	from	the	tumor.60	Oncogenic	RAS	facilitates	cancer	cell	acquisition	of	this	property	by	affecting	
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interactions	between	cells	and	the	extracellular	matrix,	and	by	promoting	cell	phenotypes	that	aid	in	migration.60	RAS	oncogenes	are	able	to	reduce	cellular	adhesion	to	the	ECM	by	decreasing	the	presence	of	integrins	that	promote	cell	linkage	to	the	ECM.82	Additionally,	cells	must	develop	a	front-rear	asymmetry	in	order	to	migrate.60	RAS	oncogenic	activity	is	able	to	induce	the	structural	shifts	necessary	for	a	cell	to	adopt	front-rear	asymmetry.60	In	order	for	a	cancer	to	continue	through	metastasis,	cancer	cells	must	be	able	to	detach	from	the	original	tumor	and	enter	the	bloodstream.	Oncogenic	activity	of	RAS	has	been	shown	to	degrade	the	ECM,	and	impact	the	integrity	of	the	basement	membrane	in	order	to	promote	angiogenesis	for	cell	proliferation.	The	degradation	of	the	basement	membrane,	which	is	vital	for	the	containment	of	cancer	cells,	and	the	increase	of	blood	vessels	near	the	tumor	aid	in	a	cells	progression	through	the	metastatic	process.60	Thus,	oncogenic	RAS	is	able	to	further	facilitate	the	migration	of	cancer	cells.	
C.3. Cancer	Therapy	via	RAS	Inhibition	RAS	has	been	shown	to	facilitate	tumor	growth	through	numerous	pathways,	and	mechanisms.	Oncogenic	activation	of	RAS	has	been	commonly	found	in	the	progression	of	human	carcinomas	via	these	pathways.62	Therefore,	the	inhibition	of	the	activation	or	function	of	RAS	oncogenes	has	been	a	major	focus	in	cancer	therapy.	There	have	been	attempts	to	completely	inhibit	the	function	of	RAS.62,83	RAS	function,	however,	is	involved	in	many	cellular	processes.	For	that	reason,	complete	inhibition	or	alteration	of	its	function	is	not	ideal.	The	focus	has	shifted	to	cancer	
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therapeutics	that	aim	to	reduce	the	effects	of	oncogenic	RAS	without	completely	abolishing	all	of	its	function.62	
C.4. RAS	and	the	RAF-MEK-ERK	Signaling	Pathway	
C.4.1. RAF	Structure/Function	RAF,	a	serine/threonine	kinase,	is	critical	for	cell	growth	and	regulation	in	mammals.84	RAF	is	directly	downstream	of	RAS	in	signal	transduction	pathways	that	affect	cell	apoptosis,	proliferation,	and	division.85	Furthermore,	oncogenic	RAS	variants	effectively	bind,	and	activate	RAF,	resulting	in	cell	processes	that	promote	tumor	growth.	RAS	oncogenes	have	been	shown	to	induce	tumor-related	proliferation	in	cells	by	up-regulating	cyclin	D1	and	down-regulating	a	cyclin-dependent	kinase	inhibitor,	p27,	through	RAF	and	its	signaling	pathway.86,87	Additionally,	oncogenic-RAS	mediated	signaling	through	RAF	results	in	abnormal	apoptotic	activity.	RAF	activation	results	in	both	pro-apoptotic	and	pro-survival	signaling.	The	balance	of	these	two	signaling	effects	determines	cell	action;	oncogenic	RAS	pushes	the	balance	toward	pro-survival	signaling,	and	tumor	growth.60,88	Vertebrate	genomes	encode	three	RAF	genes:	A-raf,	B-raf,	and	c-raf-1.84	All	three	genes	feature	three	highly	conserved	regions	(CR1,	CR2,	and	CR3)	within	species-dependent	conserved	variable	sequences.84	The	C1	region	contains	both	an	81	amino	acid	sequence	(residues	51-131)	binding	active	site,	and	a	zinc-finger	component.84	The	binding	active	site	is	called	the	RAS	binding	domain	(RBD),	and	provides	a	pocket	that	the	RAS	effector	domain	uses	to	bind	RAF	(Figure	10).	The	zinc-finger	of	the	CR1	region	has	been	found	to	be	involved	with	RAS	binding.(Bruder	J.T.	1992)	The	CR2	region	contains	many	serine	and	threonine	residues	that	participate	in	the	regulation	of	RAF	
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via	phosphorylation/dephosphorylation	mechanisms.	Together,	CR1	and	CR2	make	up	the	regulatory	part	of	RAF	proteins,	while	CR3	contains	the	catalytic	binding	domain	for	downstream	activation.84	RAF	mutants	with	extensions	to	the	amino	terminal	of	the	protein,	CR2	region	disrupting	mutations,	alteration	of	the	zinc-finger	structure,	and	even	complete	deletion	of	the	CR1-CR2	encoding	region,89	are	still	constitutively	active,	and	have	oncogenic	characteristics.84		
	
Figure 10. RAF-RBD contact points with the RAS effector domain. Image 
adapted from Ref. 89. 
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C.4.2. Overview	of	Signaling	Pathway	RAF	is	the	initial	protein	involved	in	the	cytoplasmic	kinase	cascade,	a	signal	transduction	pathway	that	affects	cell	proliferation	and	differentiation	(Figure	11).84	The	mechanism	of	this	kinase	cascade	is	relatively	straightforward.	RAF	activates	the	MAP/ERK	protein	kinase	(MEK),	the	RAF	protein’s	only	known	substrate.84	In	turn,	MEK	activates	the	mitogen-activated	protein	kinase	(MAPK,	or	ERK,	extracellular-signal-regulated	kinase)	which	transmits	the	initial	signal	to	various	proto-oncogenic	transcription	factors	and	other	protein	kinases.90	Cell	signal	receptors	are	connected	to	the	RAF-MEK-ERK	pathway	via	RAS.84	
	
Figure 11. The RAF-MEK-ERK kinase cascade signaling 
pathway. Image adapted from Ref. 62. 
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C.4.3. RAS	Involvement	in	Pathway	The	RAF-MEK-ERK	kinase	cascade	is	activated	by	the	binding	of	RAF	by	RAS.	It	has	been	shown	that	the	RBD	of	RAF	is	crucial	for	interactions	between	RAS	and	RAF.91,92	RAS	signaling	relies	on	a	highly	conserved	mechanism62	that	features	RAS	protein	switch	I	and	switch	II	regions	and	the	RBD	of	RAS	effector	proteins,	which	includes	over	100	other	mammalian	proteins	in	addition	to	RAF.67,91,93,94	Upon	binding,	RAS	recruits	RAF	to	the	plasma	membrane.84,95	At	the	plasma	membrane,	in	the	presence	of	co-factors,	RAF	initiates	the	cytoplasmic	kinase	cascade.		Oncogenic	activity	in	this	pathway	has	been	linked	to	malignant	transformation	of	cells,	cancer	proliferation,	and	the	evasion	of	cell	apoptosis.95	The	RAF-MEK-ERK	pathway	participates	in	the	expression	of	cyclin	D1.60	Thus,	oncogenic	RAS	can	yield	overexpression	of	cyclin	D1,	which	is	associated	with	uncontrolled	cell	growth	and	cancer	progression,	via	this	pathway.	Additionally,	the	RAF	pathway	contributes	to	the	suppression	of	cell-apoptosis	induced	by	oncogenic	RAS.	RAS-activated	RAF	downregulates	prostate	apoptosis	response	4	(PAR4),	a	protein	that	inhibits	transcription	and	acts	to	promote	apoptosis,96	and	upregulates	anti-apoptotic	factors,	such	as	BCL-2.97	Furthermore,	RAS-activated	RAF	has	been	demonstrated	to	phosphorylate	BCL-2-associated	agonist	of	cell	death	(BAD),	which	results	in	the	inactivation	of	the	BCL-2	family	anti-apoptotic	factors.98	
C.5. Past	RAS	Targeting	Drug	Therapies	RAS’	role	in	eukaryotic	kinase	pathways	positions	it	as	a	viable	drug	target	for	inhibition	of	uncontrollable	cell	growth,	and	RAS	hyperactivation.	Prevention	of	productive	interactions	between	RAS	and	its	downstream	effectors	is,	in	theory,	an	
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effective	inhibition	method.61	This	could	be	achieved	by	limiting	the	amount	of	RAS	in	the	GTP-bound	state,	reducing	the	overall	number	of	RAS	proteins	in	a	cell,	or	directly	blocking	protein-protein	interactions	between	RAS	and	its	binding	partners.61,67	While	these	seem	like	reasonable	inhibition	mechanisms,	there	is	an	issue	with	direct	RAS	inhibition.	Inhibitors	that	cannot	distinguish	between	wild-type	and	mutant	RAS	proteins	would	likely	result	in	high	levels	of	toxicity.61	Therefore,	inhibition	mechanisms	that	target	the	binding	domains	of	specific	RAS	binding	partners,	such	as	RAF	in	the	case	of	this	experiment,	can	provide	effective	RAS	inhibition,	while	reducing	resultant	toxicity.	This	is	possible	because	RAS	affects	multiple	signaling	pathways.62	By	targeting	a	specific	RAS/RAF	effector	interaction,	drugs	that	inhibit	binding	can	affect	the	mutagenic	effects	of	oncogenic	RAS	without	adversely	impacting	other	vital	RAS	function	in	the	cell.	
C.6. Rigosertib	Rigosertib,	a	benzyl	styryl	sulfone,	is	a	small	molecule	inhibitor	of	the	RBD	interactions	between	RAF	and	RAS.	The	drug	is	currently	in	phase	III	clinical	trials	for	myelodysplastic	syndrome	(MDS),	a	type	of	cancer.	Rigosertib	binds	to	the	RBDs	of	a	number	of	RAS	effectors,	and	limits	RAS’	ability	to	bind	to	them.67	This	in	turn	reduces	RAF	activity,	and	inhibits	the	RAF-MEK-ERK	pathway	(Figure	12).	Rigosertib	has	been	shown	to	inhibit	tumor	growth	in	vitro	and	limit	growth	in	vivo.67,99	
	 44	
	
Figure 12. RAS initiated RAF-MEK-MAPK signaling pathway in the 
absence and presence of Rigosertib. Image adapted from Ref. 67.  
 Rigosertib	specifically	binds	to	six	proteins:	three	RAF	variants	(A-RAF,	B-RAF,	and	C-RAF),	FUBP3,	Hsp27,	and	Hsp73.67	In	the	RAF	protein	interactions,	Rigosertib	bound	similar	residues	to	those	which	RAS	has	been	found	to	bind	(all	of	which	are	conserved	in	the	RAF	family	of	proteins).67	Based	on	these	studies,	Athuluri-Divakar	et	al.	determined	that	Rigosertib,	in	fact,	acts	as	a	RAS	mimetic	and	utilizes	a	similar	binding	mechanism	for	interactions	with	RAF.		Inhibition	of	oncogenic	RAS	activity	is	a	reasonable	and	effective	target	for	cancer	therapy.	Rigosertib	does	exactly	this.	By	acting	as	a	RAS	mimetic,	Rigosertib	
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inhibits	binding	between	RAF	and	RAS,	thus	abolishing	function	in	the	RAF-MEK-ERK	kinase	cascade.	This	drug	has	promising	implications	for	the	future	of	therapeutic	intervention	in	RAS	oncogenic	activity,	and	cancer	therapy	in	general.	RAF,	however,	may	develop	mutations	that	reduce	the	binding	affinity	of	Rigosertib.	In	the	case	that	these	mutations	also	reduce	binding	function	between	RAS	and	RAF,	they	may	not	have	oncogenic	effects;	while	Rigosertib	will	not	inhibit	RAS	and	RAF	interactions	by	binding	RAF,	the	binding	interaction	between	RAS	and	RAF	will	still	be	inhibited	by	the	mutation.	Some	mutations	may,	however,	have	oncogenic	effects.	RAF	may	develop	a	mutation	that	negatively	impacts	RAF	binding	by	Rigosertib,	yet	retains	the	binding	function	between	RAS	and	RAF.	In	this	case,	RAF	will	have	developed	functional	resistance	to	Rigosertib,	and	oncogenic	RAS	could	signal	through	the	RAF-MEK-ERK	pathway	uninhibited	by	Rigosertib.		By	combining	phage	display	selection	of	RAF	variants,	with	high-throughput	sequencing	of	variants	selected	for	binding	affinity	to	RAS	in	the	presence	of	Rigosertib,	we	can	provide	a	method	for	understanding	and	mapping	RAF	resistance	to	the	anti-cancer	drug,	Rigosertib.	This	information	can	be	used	to	alter	the	structure	of	Rigosertib	or	its	mechanism	of	binding	to	anticipate	resistance,	or	for	the	development	of	other	therapeutics.		
D. Proposed	Experiments	Our	experiment	proposes	to	pair	of	the	phage	display	of	a	library	of	RAF	variants	with	high-throughput	sequencing	of	variants	selected	for	functional	resistance	mutations	to	Rigosertib	to	shed	light	on	potential	mechanisms	for	Rigosertib	resistance	in	the	human	organism.	An	overview	of	our	experiment	is	described	in	Figure	13.		
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Figure 13. Overview of proposed experiment. 
Aim	1:	Create	library	of	RAF	mutants	and	use	phage	display	to	select	for	mutant	binding	
affinity	to	RAS	Aim	1	will	result	in	a	phage	displayed	library	of	mutant	RAF	variants	that	have	been	validated	for	binding	affinity	to	RAS.	A	library	of	RAF	variants	displayed	on	phage	will	be	created,	and	selected	for	binding	to	RAS	as	described	in	Figure	14.	Previously	characterized	effects	of	specific	RAF	mutations	will	also	be	used	to	assess	successful	library	creation.	Block	et	al.	have	characterized	specific	amino	acid	positions	found	in	the	RBD	of	RAF	(residues	51-131)	that	appear	to	be	critical	for	RAS/RAF	binding.91	This	
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data	will	be	compared	to	the	mutant	RAF	library	as	an	additional	validation	of	successful	library	creation,	and	accurate	functionality	of	the	RAF	variants.	
	
Figure 14. Schematic displaying Aim 1 selection. The phage displayed RAF variant 
library is selected for RAS binding function via biotinylated RAS, which binds to 
streptavidin beads. The selected variants are then sequenced and compared to the 
input library. 
 First,	RAF	must	be	displayed	on	phage.	The	gene	encoding	the	RAF	protein	will	be	fused	to	the	filamentous	phage	M13	gene	encoding	pIII	in	a	phagemid	vector,	and	transformed	into	E.	Coli	cells	with	the	addition	of	helper	phage	(M13KO7,	as	previously	described).18	We	have	decided	to	fuse	RAF	to	pIII	with	the	phagemid	vector	method	because	it	produces	phages	that	exhibit	monovalent	display.	Monovalency	is	desirable	as	it	reduces	any	avidity	effects	that	would	result	from	the	display	of	multiple	copies	of	RAF	on	a	single	phage.	Additionally,	since	phagemid	vector	construction	results	in	a	larger	quantity	of	wild-type	pIII	displayed	on	phage,	phage	infectivity	will	be	conserved.	Lastly,	this	method	will	facilitate	biochemical	analysis	and	sequencing	of	selected	phage;	free	expression	of	RAF	can	be	conducted	with	phagemid	vectors.	Prior	to	protein	diversification,	successful	display	on	phage	will	be	confirmed	with	a	phage	enzyme-linked	immunosorbant	assay	(ELISA),	a	successful	and	commonly	used	assay	for	display	confirmation.(	xxref	Russel	M.	Lowman	H.	B.	2004)	Upon	confirmation	of	display	on	phage,	a	library	of	RAF	variants	will	be	created.	The	library	will	be	constructed	by	random	mutagenesis	within	the	RBD	of	wild-type	
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RAF.	Error-prone	PCR,	a	variation	of	mutagenic	PCR,	can	be	used	to	introduce	non-biased,	random	mutations	within	a	desired	segment	of	a	target	sequence.100	For	the	purposes	of	this	experiment,	error-prone	PCR	provides	distinct	advantages	to	oligonucleotide	site-directed	mutagenesis,	and	In	vitro	DNA	recombination.	We	are	aiming	to	uncover	functional	mutations	within	the	RAF	RBD,	and	thus	desire	random	mutagenesis	across	the	entire	target	region.	Oligonucleotide	site-directed	mutagenesis	specifies	mutation	locations	in	the	target	sequence,	and	cannot	efficiently	produce	a	library	of	RAF	variants	with	random	RBD	mutations.	In	vitro	DNA	recombination	is	prone	to	the	loss	of	functional	mutations	as	a	result	of	the	method’s	concept.	Furthermore,	error-prone	PCR	features	a	number	of	additional	advantages.	Primarily,	it	is	a	simple	and	efficient	method.	It	closely	follows	a	well	understood	PCR	mechanism,	with	slight	variations,	and	can	produce	target	levels	of	mutagenesis	relatively	quickly.100	Furthermore,	error-prone	PCR	can	be	controlled	for	specific	rates	of	mutagenesis.101		Error-prone	PCR,	as	a	method	of	random	mutagenesis,	takes	advantage	of	the	relatively	high	error	rate	of	Taq	DNA	polymerase.	In	a	typical	PCR	reaction	the	error	rate	is	around	10-3	errors	per	nucleotide.102	The	relatively	low-fidelity	of	Taq	polymerase	can	be	further	exacerbated	by	varying	the	reaction	conditions,	such	as	increasing	the	concentration	of	Mg2+	or	Mn2+	of	the	reaction	mixture.101	Cadwell	et	al.	utilized	such	manipulation	of	reaction	conditions	to	reach	an	error	rate	of	about	7	×	103	errors	per	nucleotide	with	minimal	sequence	bias.102	Additional	parameters	may	be	altered	in	order	to	increase	or	decrease	this	error	rate	to	produce	the	desired	rate	of	mutagenesis	of	the	target	sequence.100	
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For	the	purposes	of	this	experiment,	the	aim	is	to	produce	a	library	of	mutants	that	contain	an	average	of	one	mutation	per	variant.	This	rate	of	mutagenesis	will	allow	for	the	accurate	attribution	of	any	potential	novel	function	to	a	specific	amino	acid	change.	While	variants	with	more	mutations	might	exhibit	novel	function,	it	would	be	difficult	to	link	novel	function	to	the	mutations	that	caused	them.	As	the	RBD,	an	80-residue	region,	is	composed	of	more	than	200	base-pairs	of	DNA	the	error-rate	that	Cadwell	et	al.	managed	to	reach,	a	frequency	of	0.66%±0.13%	errors	per	position,	will	be	sufficient	to	guarantee	at	least	one	mutation	per	variant.100	To	diversify	the	RAF	gene	fused	to	pIII,	error-prone	PCR	will	follow	a	standard	PCR	protocol	with	vital	modifications,	as	previously	described.102	Some	of	the	modifications	that	are	engineered	to	increase	the	mutation	rate	are:	an	increased	MgCl2	concentration	to	facilitate	the	pairing	of	noncomplementary	bases,	addition	of	MnCl2	which	increases	the	polymerases	error	rate,	an	increase	in	dCTP	and	dTTP	concentrations,	and	an	increase	in	quantity	of	Taq	polymerase	units.		We	will	confirm	that	the	error-prone	PCR	method	successfully	diversified	the	RAF	gene.		The	quantity	and	molecular	weight	of	the	product	will	be	confirmed	via	an	agarose	gel	embedded	with	ethidium	bromide.100	Lastly,	we	will	confirm	achievement	of	the	desired	mutation	rate	by	sequencing	a	sample	of	the	PCR	product.	Successful	implementation	of	this	protocol	will	result	in	a	phage	displayed	library	of	RAF	mutants	that	includes	no	more	than	108	mutants.48		 Next,	the	newly	synthesized	library	must	be	selected	for	binding	to	RAS.	Selection	will	be	achieved	by	a	solution	binding	technique;	active	RAS	binding	RAF	mutants	will	be	collected	upon	successful	binding	to	wild-type	RAS.	Solution	binding	
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was	chosen	over	alternative	selection	techniques,	such	as	immobilization,	because	it	decreases	the	likelihood	that	multiple	binding	events	occur.	This	will	mitigate	collection	of	variants	that	appear	to	have	high	binding	affinity,	but	in	reality	only	appear	to	do	so	because	of	avidity	effects.	The	wild-type	RAS,	the	substrate	in	this	case,	will	be	prepared	for	selection	via	biotinylation,	the	process	of	covalently	linking	a	biotin	molecule	to	a	protein,	or	other	molecule.	This	process	typically	does	not	impede	or	affect	protein	function	due	to	the	relatively	small	size	of	Biotin.	In	our	experiment,	wild-type	RAS	will	be	enzymatically	biotinylated.	Chemical	biotinylation,	another	major	biotinylation	method,	risks	protein	inactivation	and	low	biotinylation	yield,	while	enzymatic	biotinylation	conserves	protein	function	and	leads	to	high	yields.103	The	biotin	carboxy	carrier	protein	(BCCP),	a	13	amino	acid	peptide,	will	be	fused	to	wild-type	RAS.	This	sequence	contains	a	lysine	that	is	specifically	biotinylated	by	BirA,	a	biotin	ligase	found	in	E.	Coli.103,104	The	BCCP-tagged	RAS	will	be	transformed	into	E.	Coli	and	biotinylated	as	previously	described.104	Successful	biotinylation	will	be	verified	by	ELISA,	with	absorption	at	405	nm	directly	proportional	to	the	amount	of	biotinylated	products.104	Upon	successful	biotinylation	of	wild-type	RAS,	the	phage	library	will	be	incubated	in	solution	with	the	biotinylated	RAS.	Streptavidin-coated	magnetic	beads	will	be	added	to	the	solution.	Only	the	RAF	variants	that	retain	binding	functionality	should	bind	the	biotinylated	RAS,	and	thus	only	those	variants	will	be	attached	to	the	streptavidin	beads.	The	bound	phages	will	then	be	removed	from	the	solution	by	magnet;	the	streptavidin-coated	beads	are	magnetic.	Any	background	phage	will	be	removed	by	buffer	washes,	while	bound	phage	will	remain	bound	to	the	streptavidin	
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beads.105,106	The	selected	phage	will	then	be	eluted	from	the	beads	by	100mM	triethylamine,	a	reagent	that	is	not	toxic	to	Ff	bacteriophage.2,103		Selection	will	be	monitored	by	incubation	of	eluted	phage	samples	in	E.	Coli	cells,	as	previously	described.20	The	cells	will	be	plated,	incubated,	and	then	colonies	will	be	counted.	Phage	concentration	(cfu/ml)	will	be	determined.	A	minimum	of	104	cfu/ml	is	expected,	as	this	is	the	number	of	phage	usually	required	for	growth	in	a	culture.20	Successful	selection	of	RAS	binding	RAF	variants	will	yield	between	104	and	109	cfu/ml.	As	a	control	for	this	selection,	the	phage	library	variants	will	also	be	selected	for	in	the	absence	of	biotinylated	RAS.	None	of	the	phage	variants	should	be	attached	to	the	streptavidin	beads	in	this	trial,	if	this	is	not	the	case	then	the	phage	library	must	be	further	analyzed	to	find	the	cause	of	binding,	or	simply	re-constructed.		 Following	selection,	successful	binding	will	be	experimentally	validated.	The	bound	phages	will	then	be	sequenced,	and	compared	to	the	input	RAF	variant	library	to	control	for	library	biases	and	other	potential	artifacts.	Finally,	mutations	that	retained	RAS-binding	affinity	will	be	identified	and	compared	to	recent	studies.		 For	validation	of	binding	after	selection,	we	will	monitor	a	sample	of	5-10	of	the	selected	RAF	variants	for	binding	affinity	to	activated	RAS,	the	GTP-bound	state.	Selected	RAF	mutants	will	be	individually	incubated	in	HeLa	cells,	treated	with	DMSO,	with	glutathione	S-transferase	(GST)	fused	RASG12D	bound	to	glutathione-agarose	beads.	The	level	of	binding	for	each	RAF	variant	will	then	be	determined	by	immunoblot	analysis.	This	technique	was	chosen	as	it	has	previously	been	used	to	successfully	examine	RAF	binding	to	activated	RAS.67	GST	tagging	of	proteins	is	useful	as	it	can	be	used	to	induce	immobilization	by	glutathione,	which	will	allow	us	to	immobilize	
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functionally	binding	RAF	variants.107	HeLa	cells	are	a	desirable	medium	for	this	experiment	as	they	are	a	human	cell	line.	The	decision	to	construct	the	phage	library	with	phagemid	vectors	will	expedite	this	experiment;	phagemid	vectors	can	be	used	to	express	RAF	variants	that	are	not	linked	to	phage	via	amber	(TAG)	stop	codon	incorporation,	as	previously	described.		 Once	the	selected	RAF	variant	population	has	been	validated	for	binding	to	RAS,	it	will	be	sequenced	with	high-throughput	short-read	Illumina	sequencing	techniques,	as	previously	described.4	The	technique	requires	the	isolation	of	phage	library	DNA	by	phenol-chloroform	extraction	and	precipitation	by	ethanol.	The	DNA	is	then	amplified,	purified,	and	sequenced	using	a	Genome	Analyzer	IIx,	an	Illumina	product.	The	input	library	will	also	be	sequenced.	The	populations	will	then	be	compared	to	account	for	any	artifacts	or	library	biases.	Lastly,	mutants	that	are	validated	for	binding	affinity	to	RAS	will	then	be	compared	to	prior	studies.	Block	et	al.	found	that	mutations	at	specific	locations	within	the	RBD	of	RAF	reduced	RAF/RAS	binding	affinity	(Figure	15).91	Validation	of	the	library	of	RAF	variants	will	depend	on	the	mutations	found	in	variants	that	were	selected	for	RAS	binding.	This	method	will	serve	as	a	secondary	validation.	If	any	of	the	selected	variants	contain	mutations	that	have	been	found	to	reduce	binding	affinity,	then	there	are	three	plausible	explanations.	First,	the	less	likely	explanation,	the	findings	in	previous	studies	may	be	incorrect,	such	that	the	mutations	that	have	been	found	to	impede	RAF/RAS	binding	actually	do	not	do	so.	Second,	the	much	more	likely	explanation,	it	is	possible	that	the	creation	of	the	phage	library	either	didn’t	successfully	incorporate	mutations	into	the	RAF	sequence,	or	that	the	RAF	variants	were	not	
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successfully	displayed	on	the	bacteriophage.	Third,	it	is	also	possible	that	these	mutant	variants	contain	more	than	one	mutation,	and	that	the	additional	mutation(s)	restored	function	in	RAF	in	the	presence	of	the	function	inhibiting	mutation.	In	either	case,	these	findings	would	require	troubleshooting	and	additional	analysis;	anywhere	from	re-sequencing	the	selected	variants	to	re-constructing	the	phage	library.		
	
Figure 15. RAF mutations with known negative 
impacts on RAS binding affinity. This will be used as 
an additional validation of the library of RAF mutants. 
Variants that bind RAS should not contain any of 
these mutations. Image adapted from Ref. 91. 
 
Aim	2:	Use	phage	display	to	identify	RAF	mutants	that	exhibit	resistance	to	Rigosertib	
while,	simultaneously,	retaining	binding	affinity	to	RAS	The	goal	of	incorporating	Rigosertib	as	a	selection	condition	is	to	evaluate	whether	the	selected	RAF	variants	have	developed	the	novel	function	of	resistance	to	
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RAS-mimetic	cancer	therapeutics,	primarily	Rigosertib.	Theoretically,	RAF	variants,	that	have	been	validated	for	binding	to	RAS,	that	are	able	to	retain	binding	affinity	for	RAS	in	the	presence	of	Rigosertib	will	have	developed	resistance	to	the	cancer	drug.	These	variants	can	then	be	characterized	to	determine	which	mutations	developed	this	resistance	in	the	variant.	Identification	of	functional	resistance	mutations	to	Rigosertib	can	provide	vital	insight	for	future	cancer	therapy.		Once	the	phage	library	of	RAF	variants	has	been	validated,	it	will	be	used	to	select	for	RAF/RAS	binding	function	retaining	RAF	mutants	with	developed	resistance	to	Rigosertib	as	described	in	Figure	16.	Following	selection	and	purification	of	these	mutants,	they	will	be	characterized	by	high-throughput	sequencing	and	mapped	to	display	mutational	tolerance	and	function	conservation	in	the	RBD.	
	
Figure 16. Schematic displaying Aim 2 selection strategy. The phage displayed RAF 
variant library undergoes two rounds of selection for RAS binding: in the absence 
and presence of Rigosertib, the RAS mimetic inhibitor. Both sets of selected mutants 
are sequenced, and compared to the input library. 
 The	same	phage	library,	which	has	already	been	subjected	to	two	selection	trials	(no	RAS	in	the	selection	conditions,	and	then	with	the	addition	of	biotinylated	RAS),	will	undergo	another	selection	trial.	The	library	must	now	be	selected	for	RAS	binding	in	the	
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presence	of	Rigosertib,	the	RAS	mimetic.	The	selection	conditions	will	likely	remain	similar	to	the	two	other	trials,	with	the	exception	of	the	presence	of	the	inhibitory	drug.	Due	to	the	mimetic	nature	of	Rigosertib,	it	is	likely	that	RAF	mutations	that	reduce	RAF/RAS	binding	affinity	will	also	interfere	with	the	binding	of	Rigosertib.	Variants	for	which	this	is	the	case	will	be	washed	away	during	selection,	as	they	will	not	be	able	to	bind	the	biotinylated-RAS	regardless	of	their	resistance	to	Rigosertib.	This	is	to	be	expected.	In	fact,	these	variants	are	of	little	interest	outside	of	the	role	they	may	play	in	validating	the	mechanism	with	which	Rigosertib	binds	to	RAF.	The	variants	that	are	selected,	via	immobilization	by	streptavidin	beads,	will	feature	mutations	that	inhibit	Rigosertib	binding	while	retaining	RAF/RAS	binding	function.	Multiple	rounds	of	selection	are	expected	to	produce	a	small	subset	(50-100	variants)	of	the	original	phage	library	that	exhibit	high	affinity	for	Rigosertib	resistance	and	RAS	binding.	At	this	point,	short-read	Illumina	sequencing	will	be	used	to	sequence	these	Rigosertib-resistant	RAF	variants,	as	previously	described.4	This	sequence	data	will	be	compared	to	the	data	of	the	pre-selection	input	library,	and	the	phage	selected	in	the	absence	of	Rigosertib	to	control	for	library	biases	and	artifacts.	The	sequence	data	will	also	be	used	to	map	the	prevailing	mutations	that	conferred	desired	function	with	a	sequence	logo,	as	previously	described	(Figure	17).108	These	results	will	highlight	vital	mutations	for	resistance	to	Rigosertib,	thus	providing	critical	insight	into	potential	mechanisms	of	resistance	that	may	arise	to	the	use	of	Rigosertib	as	a	cancer	therapy	treatment.	
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Figure 17. Sample sequence logo. DNA sequences are aligned and used to create 
a sequence logo that highlights conserved nucleotides. This technique will be used  
to compare amino acid sequences of selected RAF variants. Image adapted from 
Ref. 108. 
 
Aim	3:	Test	selected	mutants	for	functionality	within	the	RAF-MEK-ERK	pathway	The	goal	of	Aim	3	is	to	determine	the	downstream	functionality	of	RAF	variants	that	have	gained	RAS/RAF	functional	resistance	to	Rigosertib.	While	these	variants	
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have	displayed	the	ability	to	resist	binding	by	Rigosertib,	and	can	still	be	bound	by	RAS,	they	will	not	have	an	oncogenic	effect	if	they	cannot	be	activated	by	RAS,	or	if	they	cannot	continue	the	signal	transduction	pathway	through	MEK	and	ERK.	Therefore,	selected	variants	must	be	analyzed	for	functional	binding	and	activation	of	the	other	components	of	the	cytoplasmic	kinase	cascade.		 Selected	RAF	variants	will	be	tested	for	functional	signaling	activity	in	the	RAF-MEK-ERK	pathway.	The	MEK-ERK	pathway	activation	assay	and	subsequent	protein	analysis	that	will	be	used	have	been	previously	described,	and	conditions	are	shown	in	Table	X.67	HeLa	cells	will	be	incubated	with	DMSO	(negative	control),	or	Rigosertib	and	treated	with	epidermal	growth	factor	(EGF),	which	activates	RAS.67	The	cell	lysates	will	then	be	treated	with	each	of	the	Rigosertib-resistant	RAF	variants,	following	variant	expression.	Co-immunoprecipitation	assays	with	RAF-specific	antibodies	and	western	blot	analyses	will	be	used	to	determine	the	level	of	RAF	heterodimerization	(a	vital	function	of	wild-type	RAF	upon	RAS	activation),	the	level	of	phosphorylated-ERK	relative	to	total	ERK,	and	the	level	of	phosphorylated-MEK	relative	to	total	MEK.	Functional	signaling	RAF	variants	will	readily	form	heterodimers,	and	will	induce	downstream	phosphorylation	with	little	to	no	change	relative	to	wild-type	levels.67			 This	method	was	chosen	over	others,	such	as	the	MAP/ERK	Kinase	Assay,109	because	of	its	similarity	to	the	techniques	that	we	will	use	to	validate	binding	affinity	in	Aim	1.	We	will	not	need	to	obtain	many	new	reagents,	or	a	new	cell	line.	Additionally,	this	technique	has	successfully	assessed	RAF	signaling	function	in	previous	studies.	This	experiment	will	identify	and	characterize	mutants	that	successfully	activate	downstream	kinases,	thus	completing	signal	transduction.	These	mutants	will	
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represent	fully	functional	mechanisms	for	RAF	resistance	to	Rigosertib,	and	potentially	other	RAS	mimetic	drugs.		
D.1. 	Significance	Successful	implementation	of	this	experiment	will	yield	vital	information	and	insight	into	the	use	of	Rigosertib,	and	other	RAS	mimetic	therapeutics,	as	a	cancer	therapy	treatment.	Pharmacologists	and	doctors	may	be	able	to	anticipate	resistance	to	Rigosertib	in	vivo	and	administer	treatments	that	can	counter	or	prevent	the	development	of	RAF	resistance.	Rigosertib	could,	for	example,	be	coupled	with	another	therapeutic	cancer	drug	to	anticipate	resistance	and	prevent	a	second	wave	of	oncogenic	RAF	mutants.	Furthermore,	the	experiment	may	uncover	mutants	that,	in	addition	to	resisting	Rigosertib,	successfully	activate	downstream	kinases,	thus	completing	signal	transduction.	These	mutants	will	be	identified	and	characterized,	thus	improving	understanding	of	the	binding	mechanism	of	RAF	and	RAS,	and	their	interactions	with	downstream	kinases.	The	development	of	additional	drug	therapies	will	be	aided	by	this	characterization	of	oncogenic	activity	of	RAF	and	RAS	in	the	cytoplasmic	kinase	cascade	signaling	pathway.	
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